Teva Pharmaceutical Industries (FRA:TEV) EPS without NRI: €2.52 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
57 GF Score
Price €26.70
GF Value €17.22
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries EPS without NRI?

Teva Pharmaceutical Industries FRA:TEV -1.84% 57 EPS without NRI is €2.52 as of Mar. 2026. GuruFocus rates FRA:TEV with a GF Score™ of 57/100 and a GF Value™ of €17.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 788 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 56.98% on this metric.

Teva Pharmaceutical Industries's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €0.46. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €2.52.

During the past 12 months, Teva Pharmaceutical Industries's average earnings per share (NRI) Growth Rate was 15.80% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 5.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.60% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was -6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Teva Pharmaceutical Industries's EPS without NRI or its related term are showing as below:

FRA:TEV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.5   Med: 10.8   Max: 76.9
Current: 5.2

During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 76.90% per year. The lowest was -33.50% per year. And the median was 10.80% per year.

FRA:TEV's 3-Year EPS without NRI Growth Rate is ranked worse than
56.98% of 788 companies
in the Drug Manufacturers industry
Industry Median: 9.65 vs FRA:TEV: 5.20

Teva Pharmaceutical Industries's EPS (Diluted) for the three months ended in Mar. 2026 was €0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.14.

Teva Pharmaceutical Industries's EPS (Basic) for the three months ended in Mar. 2026 was €0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.18.


Teva Pharmaceutical Industries  (FRA:TEV) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Teva Pharmaceutical Industries EPS without NRI Related Terms


Teva Pharmaceutical Industries EPS without NRI Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries EPS without NRI Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 2.38 2.35 2.38 2.50

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.57 0.67 0.82 0.46

FRA:TEV vs ZTS, UTHR, VTRS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's PE Ratio without NRI falls into.


FRA:TEV
57GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €2.52 mean?
Teva Pharmaceutical Industries (FRA:TEV) has a EPS without NRI of €2.52 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Teva Pharmaceutical Industries and its competitors. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #449 out of 788 companies in the Drug Manufacturers industry, placing it in the top 57%.
Is Teva Pharmaceutical Industries' EPS without NRI too high?
Teva Pharmaceutical Industries' current EPS without NRI is €2.52. Based on the distribution chart, Teva Pharmaceutical Industries ranks #449 out of 788 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #449 out of 788 companies for EPS without NRI. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current EPS without NRI is €2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.22, compared to a current price of €26.70 — trading 55.1% above its estimated fair value. The current EPS without NRI is €2.52. Teva Pharmaceutical Industries' overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current EPS without NRI is €2.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €26.70 is trading 55.1% above its estimated GF Value™ of €17.22. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • EPS without NRI: €2.52
  • GF Value™: €17.22 vs. price of €26.70 (55.1% above fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
57GF Score

Get the complete analysis for FRA:TEV

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.70
Price
€17.22
GF Value